Kathryn Hassell
Concepts (536)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anemia, Sickle Cell | 48 | 2026 | 302 | 7.040 |
Why?
| | Water Pollutants, Chemical | 13 | 2022 | 231 | 2.130 |
Why?
| | Antiphospholipid Syndrome | 5 | 2023 | 32 | 1.740 |
Why?
| | Migraine Disorders | 2 | 2023 | 109 | 1.270 |
Why?
| | Anticoagulants | 8 | 2021 | 718 | 1.130 |
Why?
| | Perciformes | 5 | 2018 | 19 | 1.120 |
Why?
| | Heparin | 5 | 2011 | 250 | 1.080 |
Why?
| | Thrombocytopenia | 5 | 2014 | 206 | 1.070 |
Why?
| | Antibodies, Antiphospholipid | 4 | 2023 | 23 | 1.020 |
Why?
| | Fishes | 4 | 2021 | 110 | 1.000 |
Why?
| | Hypertension, Pulmonary | 13 | 2026 | 1976 | 0.940 |
Why?
| | Estrogens | 3 | 2016 | 372 | 0.780 |
Why?
| | Hydroxyurea | 5 | 2016 | 34 | 0.770 |
Why?
| | Hemopexin | 4 | 2025 | 36 | 0.740 |
Why?
| | Pyridones | 2 | 2021 | 198 | 0.700 |
Why?
| | Disorders of Sex Development | 2 | 2018 | 40 | 0.670 |
Why?
| | Blood Transfusion | 7 | 2015 | 402 | 0.660 |
Why?
| | Hirudins | 4 | 2011 | 52 | 0.660 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2023 | 238 | 0.640 |
Why?
| | Fibrinolytic Agents | 2 | 2021 | 285 | 0.640 |
Why?
| | Testis | 2 | 2018 | 166 | 0.630 |
Why?
| | Hemoglobins | 8 | 2021 | 373 | 0.630 |
Why?
| | Caprylates | 1 | 2020 | 27 | 0.620 |
Why?
| | Alkanesulfonic Acids | 1 | 2020 | 49 | 0.610 |
Why?
| | Pyrazoles | 2 | 2021 | 496 | 0.610 |
Why?
| | Environmental Monitoring | 8 | 2025 | 377 | 0.590 |
Why?
| | Oocytes | 2 | 2021 | 177 | 0.570 |
Why?
| | Quality of Life | 6 | 2017 | 3068 | 0.550 |
Why?
| | Fluorocarbons | 1 | 2020 | 142 | 0.540 |
Why?
| | Neonatal Screening | 3 | 2020 | 174 | 0.530 |
Why?
| | Cyprinidae | 1 | 2016 | 22 | 0.480 |
Why?
| | Pain | 5 | 2023 | 771 | 0.480 |
Why?
| | Australia | 10 | 2022 | 283 | 0.480 |
Why?
| | Haptoglobins | 3 | 2025 | 64 | 0.470 |
Why?
| | Pain Measurement | 3 | 2017 | 547 | 0.410 |
Why?
| | beta-Thalassemia | 2 | 2025 | 38 | 0.410 |
Why?
| | Embryo, Nonmammalian | 2 | 2019 | 168 | 0.410 |
Why?
| | Health Status Indicators | 1 | 2014 | 160 | 0.400 |
Why?
| | Surveys and Questionnaires | 4 | 2017 | 5952 | 0.400 |
Why?
| | Patient Outcome Assessment | 1 | 2014 | 132 | 0.400 |
Why?
| | Tricuspid Valve Insufficiency | 3 | 2011 | 22 | 0.380 |
Why?
| | Humans | 78 | 2026 | 142675 | 0.370 |
Why?
| | Adult | 41 | 2025 | 39754 | 0.370 |
Why?
| | Peptide Fragments | 4 | 2014 | 700 | 0.360 |
Why?
| | Sewage | 2 | 2025 | 32 | 0.340 |
Why?
| | Antithrombins | 2 | 2011 | 70 | 0.340 |
Why?
| | Thrombosis | 4 | 2021 | 390 | 0.340 |
Why?
| | Empirical Research | 1 | 2011 | 21 | 0.340 |
Why?
| | Animals | 30 | 2026 | 37904 | 0.330 |
Why?
| | Evidence-Based Medicine | 5 | 2017 | 705 | 0.330 |
Why?
| | Male | 48 | 2025 | 71074 | 0.320 |
Why?
| | Nomograms | 1 | 2011 | 58 | 0.320 |
Why?
| | Censuses | 1 | 2010 | 35 | 0.310 |
Why?
| | Endocrine Disruptors | 3 | 2016 | 43 | 0.310 |
Why?
| | Female | 43 | 2025 | 76889 | 0.300 |
Why?
| | Vitellogenins | 3 | 2016 | 11 | 0.290 |
Why?
| | Rivaroxaban | 2 | 2025 | 268 | 0.290 |
Why?
| | Heme | 3 | 2025 | 86 | 0.290 |
Why?
| | Venous Thromboembolism | 2 | 2025 | 330 | 0.290 |
Why?
| | Health Priorities | 1 | 2009 | 43 | 0.280 |
Why?
| | Thrombophilia | 3 | 2007 | 87 | 0.280 |
Why?
| | Young Adult | 18 | 2025 | 13817 | 0.280 |
Why?
| | Carotid Artery, Internal, Dissection | 1 | 2008 | 14 | 0.270 |
Why?
| | Estuaries | 2 | 2021 | 2 | 0.270 |
Why?
| | Iron | 4 | 2025 | 350 | 0.270 |
Why?
| | Gonads | 2 | 2018 | 23 | 0.270 |
Why?
| | Self Care | 1 | 2010 | 393 | 0.260 |
Why?
| | Hypoxia | 4 | 2026 | 1193 | 0.260 |
Why?
| | Stroke | 3 | 2021 | 1216 | 0.260 |
Why?
| | Heart Septal Defects, Atrial | 2 | 2005 | 58 | 0.260 |
Why?
| | Population Surveillance | 2 | 2010 | 490 | 0.260 |
Why?
| | Nitric Oxide | 2 | 2018 | 902 | 0.260 |
Why?
| | Sickle Cell Trait | 2 | 2018 | 14 | 0.250 |
Why?
| | Fresh Water | 3 | 2020 | 56 | 0.250 |
Why?
| | Hospitalists | 1 | 2011 | 265 | 0.250 |
Why?
| | Middle Aged | 25 | 2025 | 35224 | 0.250 |
Why?
| | Kinetics | 2 | 2020 | 1613 | 0.240 |
Why?
| | Biodiversity | 2 | 2021 | 424 | 0.240 |
Why?
| | Phospholipids | 1 | 2008 | 211 | 0.240 |
Why?
| | Insecta | 1 | 2006 | 74 | 0.240 |
Why?
| | Estradiol | 4 | 2016 | 527 | 0.240 |
Why?
| | Acoustics | 1 | 2026 | 50 | 0.240 |
Why?
| | Environmental Pollutants | 2 | 2019 | 162 | 0.230 |
Why?
| | Fats | 1 | 2025 | 18 | 0.230 |
Why?
| | Pregnancy Complications, Hematologic | 1 | 2005 | 25 | 0.230 |
Why?
| | Patient Education as Topic | 1 | 2010 | 783 | 0.230 |
Why?
| | Cation Transport Proteins | 1 | 2026 | 116 | 0.220 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2025 | 677 | 0.220 |
Why?
| | Adolescent | 20 | 2025 | 22135 | 0.220 |
Why?
| | Health Services Accessibility | 3 | 2016 | 1066 | 0.220 |
Why?
| | Estrone | 2 | 2016 | 40 | 0.220 |
Why?
| | Hospitalization | 4 | 2025 | 2329 | 0.220 |
Why?
| | Spleen | 2 | 2025 | 514 | 0.210 |
Why?
| | Lung | 4 | 2025 | 4131 | 0.210 |
Why?
| | Hypertrichosis | 1 | 2023 | 8 | 0.200 |
Why?
| | Cadmium | 2 | 2021 | 68 | 0.200 |
Why?
| | Hemoglobinopathies | 1 | 2023 | 6 | 0.190 |
Why?
| | Factor Xa Inhibitors | 1 | 2025 | 188 | 0.190 |
Why?
| | Antisickling Agents | 2 | 2016 | 7 | 0.190 |
Why?
| | Acromegaly | 1 | 2023 | 17 | 0.190 |
Why?
| | Limb Deformities, Congenital | 1 | 2023 | 21 | 0.190 |
Why?
| | Headache | 2 | 2023 | 152 | 0.190 |
Why?
| | Wetlands | 2 | 2022 | 32 | 0.190 |
Why?
| | Hemostasis | 2 | 2007 | 101 | 0.190 |
Why?
| | Bays | 3 | 2017 | 7 | 0.190 |
Why?
| | Child | 20 | 2024 | 22376 | 0.190 |
Why?
| | Psychometrics | 3 | 2016 | 722 | 0.180 |
Why?
| | Pesticides | 1 | 2022 | 63 | 0.180 |
Why?
| | Severity of Illness Index | 3 | 2021 | 2905 | 0.180 |
Why?
| | Volatile Organic Compounds | 1 | 2023 | 63 | 0.180 |
Why?
| | Recombinant Proteins | 4 | 2011 | 1349 | 0.180 |
Why?
| | Mass Screening | 1 | 2011 | 1317 | 0.180 |
Why?
| | Arginine | 2 | 2015 | 265 | 0.180 |
Why?
| | Hemolysis | 4 | 2021 | 240 | 0.170 |
Why?
| | Metallothionein | 1 | 2021 | 25 | 0.170 |
Why?
| | Arterial Occlusive Diseases | 1 | 2021 | 88 | 0.170 |
Why?
| | alpha-Thalassemia | 1 | 2020 | 5 | 0.170 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 2021 | 80 | 0.170 |
Why?
| | Desogestrel | 1 | 2021 | 46 | 0.160 |
Why?
| | Acute Pain | 1 | 2021 | 54 | 0.160 |
Why?
| | Fertility Preservation | 1 | 2021 | 53 | 0.160 |
Why?
| | Purinergic P2Y Receptor Antagonists | 1 | 2021 | 68 | 0.160 |
Why?
| | Extracellular Vesicles | 1 | 2023 | 159 | 0.160 |
Why?
| | Proteome | 1 | 2025 | 497 | 0.160 |
Why?
| | Infertility, Female | 1 | 2021 | 111 | 0.160 |
Why?
| | Ecotoxicology | 1 | 2019 | 3 | 0.160 |
Why?
| | Partial Thromboplastin Time | 2 | 2011 | 52 | 0.150 |
Why?
| | Disease Models, Animal | 7 | 2026 | 4528 | 0.150 |
Why?
| | Vascular Remodeling | 2 | 2019 | 203 | 0.150 |
Why?
| | Polycyclic Aromatic Hydrocarbons | 2 | 2016 | 29 | 0.150 |
Why?
| | Clove Oil | 1 | 2019 | 1 | 0.150 |
Why?
| | Eugenol | 1 | 2019 | 4 | 0.150 |
Why?
| | Aged | 11 | 2025 | 25297 | 0.150 |
Why?
| | Iron Chelating Agents | 2 | 2011 | 18 | 0.150 |
Why?
| | Cyprinodontiformes | 1 | 2019 | 5 | 0.150 |
Why?
| | Multiple Organ Failure | 2 | 2005 | 125 | 0.150 |
Why?
| | Iron Overload | 2 | 2011 | 19 | 0.150 |
Why?
| | Benzoates | 2 | 2011 | 49 | 0.150 |
Why?
| | Exercise Tolerance | 2 | 2011 | 285 | 0.150 |
Why?
| | Prospective Studies | 9 | 2025 | 7845 | 0.150 |
Why?
| | Unrelated Donors | 1 | 2019 | 38 | 0.150 |
Why?
| | Liver | 3 | 2025 | 1838 | 0.150 |
Why?
| | Plastics | 1 | 2019 | 48 | 0.150 |
Why?
| | Hemorrhage | 2 | 2021 | 795 | 0.140 |
Why?
| | Altitude | 3 | 2018 | 474 | 0.140 |
Why?
| | Reproducibility of Results | 3 | 2017 | 3362 | 0.140 |
Why?
| | Signal Transduction | 2 | 2013 | 5193 | 0.140 |
Why?
| | Anesthetics | 1 | 2019 | 96 | 0.140 |
Why?
| | Triazoles | 2 | 2011 | 165 | 0.140 |
Why?
| | Practice Guidelines as Topic | 3 | 2015 | 1521 | 0.130 |
Why?
| | Europe | 2 | 2016 | 407 | 0.130 |
Why?
| | Bone Marrow Transplantation | 1 | 2019 | 292 | 0.130 |
Why?
| | Lipids | 2 | 2023 | 697 | 0.130 |
Why?
| | Surgical Procedures, Operative | 2 | 2014 | 266 | 0.130 |
Why?
| | Aspirin | 1 | 2021 | 389 | 0.130 |
Why?
| | Physical Exertion | 1 | 2018 | 211 | 0.130 |
Why?
| | Lipoproteins | 1 | 2018 | 161 | 0.130 |
Why?
| | Factor Analysis, Statistical | 2 | 2016 | 289 | 0.130 |
Why?
| | Cohort Studies | 7 | 2018 | 5820 | 0.130 |
Why?
| | Prevalence | 4 | 2024 | 2805 | 0.130 |
Why?
| | Climate Change | 1 | 2019 | 193 | 0.130 |
Why?
| | Platelet Factor 4 | 2 | 2008 | 35 | 0.130 |
Why?
| | Biomarkers | 6 | 2026 | 4227 | 0.130 |
Why?
| | Pulmonary Artery | 4 | 2019 | 1137 | 0.130 |
Why?
| | Treatment Outcome | 6 | 2025 | 11341 | 0.130 |
Why?
| | Zinc | 1 | 2020 | 295 | 0.130 |
Why?
| | Toll-Like Receptor 9 | 1 | 2017 | 37 | 0.130 |
Why?
| | Graft vs Host Disease | 1 | 2019 | 261 | 0.120 |
Why?
| | Osmeriformes | 1 | 2016 | 1 | 0.120 |
Why?
| | Carps | 1 | 2016 | 4 | 0.120 |
Why?
| | United States | 11 | 2023 | 15496 | 0.120 |
Why?
| | Phenylketonurias | 1 | 2016 | 15 | 0.120 |
Why?
| | Asia | 1 | 2016 | 68 | 0.120 |
Why?
| | Heart Diseases | 1 | 2019 | 340 | 0.120 |
Why?
| | Principal Component Analysis | 2 | 2016 | 197 | 0.120 |
Why?
| | Employment | 2 | 2014 | 180 | 0.120 |
Why?
| | Olfactory Perception | 1 | 2016 | 18 | 0.120 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2019 | 645 | 0.120 |
Why?
| | Metals, Heavy | 1 | 2016 | 31 | 0.120 |
Why?
| | Rivers | 1 | 2016 | 67 | 0.120 |
Why?
| | Trace Elements | 1 | 2016 | 51 | 0.120 |
Why?
| | Anesthesia | 1 | 2019 | 245 | 0.120 |
Why?
| | Erythrocyte Transfusion | 2 | 2015 | 225 | 0.120 |
Why?
| | Mice | 8 | 2026 | 18309 | 0.120 |
Why?
| | Macrophages | 2 | 2023 | 1503 | 0.120 |
Why?
| | Infant, Newborn | 5 | 2024 | 6315 | 0.120 |
Why?
| | Thalassemia | 1 | 2015 | 7 | 0.110 |
Why?
| | Copper | 1 | 2016 | 111 | 0.110 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2021 | 932 | 0.110 |
Why?
| | Retrospective Studies | 8 | 2021 | 16647 | 0.110 |
Why?
| | North America | 1 | 2016 | 309 | 0.110 |
Why?
| | Lung Diseases | 2 | 2019 | 788 | 0.110 |
Why?
| | Splenic Infarction | 1 | 2014 | 1 | 0.110 |
Why?
| | Fatigue | 1 | 2017 | 352 | 0.110 |
Why?
| | Protein S Deficiency | 1 | 1994 | 7 | 0.110 |
Why?
| | Zebrafish | 1 | 2019 | 515 | 0.110 |
Why?
| | Dalteparin | 1 | 2014 | 10 | 0.110 |
Why?
| | Blood Component Removal | 1 | 2014 | 28 | 0.110 |
Why?
| | Complement Inactivator Proteins | 1 | 1994 | 39 | 0.110 |
Why?
| | Quality of Health Care | 2 | 2016 | 639 | 0.110 |
Why?
| | Transplantation Conditioning | 1 | 2015 | 188 | 0.110 |
Why?
| | Blood Loss, Surgical | 1 | 2014 | 112 | 0.100 |
Why?
| | Postoperative Hemorrhage | 1 | 2014 | 95 | 0.100 |
Why?
| | Thromboembolism | 1 | 2014 | 123 | 0.100 |
Why?
| | Leg Ulcer | 1 | 2013 | 4 | 0.100 |
Why?
| | Larva | 2 | 2019 | 239 | 0.100 |
Why?
| | Blood Flow Velocity | 2 | 2014 | 413 | 0.100 |
Why?
| | Mice, Inbred C57BL | 5 | 2025 | 6007 | 0.100 |
Why?
| | Ethinyl Estradiol | 1 | 2012 | 15 | 0.100 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 850 | 0.100 |
Why?
| | Thrombin | 2 | 2023 | 170 | 0.100 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2013 | 109 | 0.100 |
Why?
| | Venous Thrombosis | 2 | 2005 | 194 | 0.090 |
Why?
| | Sex Factors | 3 | 2019 | 2066 | 0.090 |
Why?
| | Neoplasms | 2 | 2021 | 2798 | 0.090 |
Why?
| | Societies, Medical | 1 | 2017 | 862 | 0.090 |
Why?
| | Racism | 1 | 2014 | 149 | 0.090 |
Why?
| | Preoperative Care | 2 | 2005 | 376 | 0.090 |
Why?
| | Testosterone | 1 | 2016 | 423 | 0.090 |
Why?
| | Chronic Pain | 1 | 2017 | 283 | 0.090 |
Why?
| | Pharmacists | 1 | 2014 | 239 | 0.090 |
Why?
| | Patient Reported Outcome Measures | 1 | 2016 | 461 | 0.090 |
Why?
| | Hemoglobin SC Disease | 3 | 1998 | 14 | 0.090 |
Why?
| | Endothelium, Vascular | 1 | 2018 | 963 | 0.090 |
Why?
| | Prostheses and Implants | 2 | 2021 | 140 | 0.090 |
Why?
| | Ambulatory Care | 1 | 2016 | 588 | 0.090 |
Why?
| | Child, Preschool | 10 | 2024 | 11599 | 0.090 |
Why?
| | Analgesics, Opioid | 3 | 2023 | 1131 | 0.090 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2012 | 554 | 0.090 |
Why?
| | Mortality | 2 | 2012 | 360 | 0.080 |
Why?
| | Creatinine | 2 | 2014 | 491 | 0.080 |
Why?
| | Pipecolic Acids | 1 | 2011 | 26 | 0.080 |
Why?
| | Transfusion Reaction | 1 | 2011 | 62 | 0.080 |
Why?
| | Hemofiltration | 1 | 2010 | 23 | 0.080 |
Why?
| | Sulfones | 1 | 2011 | 127 | 0.080 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2013 | 622 | 0.080 |
Why?
| | Awareness | 1 | 2010 | 106 | 0.080 |
Why?
| | Disease Progression | 4 | 2023 | 2851 | 0.080 |
Why?
| | Disease Management | 2 | 2011 | 636 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2016 | 2008 | 0.070 |
Why?
| | Vasodilator Agents | 1 | 2011 | 330 | 0.070 |
Why?
| | United Kingdom | 3 | 2014 | 328 | 0.070 |
Why?
| | Career Choice | 1 | 2010 | 234 | 0.070 |
Why?
| | Echocardiography | 1 | 2011 | 641 | 0.070 |
Why?
| | Piperazines | 1 | 2011 | 385 | 0.070 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2008 | 85 | 0.070 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2011 | 369 | 0.070 |
Why?
| | Drug Utilization Review | 1 | 2008 | 59 | 0.070 |
Why?
| | Seawater | 1 | 2008 | 31 | 0.070 |
Why?
| | Anaerobiosis | 1 | 2008 | 65 | 0.070 |
Why?
| | Kidney Function Tests | 1 | 2008 | 156 | 0.070 |
Why?
| | Pregnancy | 3 | 2005 | 7128 | 0.070 |
Why?
| | Oxidation-Reduction | 3 | 2018 | 1090 | 0.070 |
Why?
| | Aged, 80 and over | 4 | 2025 | 8009 | 0.070 |
Why?
| | Software | 1 | 2013 | 682 | 0.070 |
Why?
| | Body Size | 1 | 2008 | 94 | 0.070 |
Why?
| | Cost of Illness | 1 | 2010 | 315 | 0.070 |
Why?
| | Community Participation | 1 | 2009 | 134 | 0.070 |
Why?
| | Depression | 1 | 2017 | 1501 | 0.070 |
Why?
| | Endothelial Cells | 1 | 2013 | 854 | 0.070 |
Why?
| | Histocompatibility Testing | 2 | 2019 | 120 | 0.070 |
Why?
| | Metabolomics | 1 | 2013 | 718 | 0.070 |
Why?
| | Lipid Peroxidation | 2 | 2018 | 160 | 0.060 |
Why?
| | Proteomics | 2 | 2025 | 1167 | 0.060 |
Why?
| | Deferoxamine | 1 | 2007 | 25 | 0.060 |
Why?
| | Chironomidae | 1 | 2006 | 1 | 0.060 |
Why?
| | Double-Blind Method | 3 | 2023 | 1999 | 0.060 |
Why?
| | Sulfonamides | 1 | 2011 | 569 | 0.060 |
Why?
| | Age Factors | 2 | 2014 | 3266 | 0.060 |
Why?
| | Environmental Exposure | 3 | 2019 | 583 | 0.060 |
Why?
| | Acute Kidney Injury | 2 | 2010 | 843 | 0.060 |
Why?
| | Rhabdomyolysis | 2 | 2018 | 23 | 0.060 |
Why?
| | Urbanization | 2 | 2016 | 28 | 0.060 |
Why?
| | Algorithms | 1 | 2014 | 1816 | 0.060 |
Why?
| | Registries | 2 | 2023 | 2224 | 0.060 |
Why?
| | Social Support | 1 | 2010 | 634 | 0.060 |
Why?
| | Sodium Chloride | 1 | 2006 | 141 | 0.060 |
Why?
| | Coronary Angiography | 1 | 2008 | 311 | 0.060 |
Why?
| | Time Factors | 3 | 2019 | 7008 | 0.060 |
Why?
| | Body Weight | 2 | 2021 | 989 | 0.060 |
Why?
| | Erythrocytes | 2 | 2026 | 746 | 0.060 |
Why?
| | Fibrinolysis | 2 | 1998 | 162 | 0.060 |
Why?
| | Oils | 1 | 2025 | 22 | 0.060 |
Why?
| | Health Care Surveys | 2 | 2020 | 533 | 0.060 |
Why?
| | Dermatan Sulfate | 1 | 2005 | 4 | 0.060 |
Why?
| | Species Specificity | 1 | 2006 | 571 | 0.060 |
Why?
| | Captopril | 1 | 2005 | 11 | 0.060 |
Why?
| | Factor V | 1 | 2005 | 26 | 0.060 |
Why?
| | Waste Disposal, Fluid | 1 | 2025 | 53 | 0.060 |
Why?
| | Chondroitin Sulfates | 1 | 2005 | 35 | 0.050 |
Why?
| | Ecosystem | 2 | 2021 | 582 | 0.050 |
Why?
| | Survival Analysis | 1 | 2008 | 1323 | 0.050 |
Why?
| | Angina, Unstable | 1 | 2005 | 78 | 0.050 |
Why?
| | Heme Oxygenase-1 | 1 | 2025 | 74 | 0.050 |
Why?
| | Infant Mortality | 1 | 2005 | 122 | 0.050 |
Why?
| | Risk | 2 | 2005 | 897 | 0.050 |
Why?
| | Polysaccharides | 1 | 2005 | 88 | 0.050 |
Why?
| | Standard of Care | 1 | 2025 | 79 | 0.050 |
Why?
| | Public Health Surveillance | 1 | 2024 | 83 | 0.050 |
Why?
| | Chest Pain | 1 | 2005 | 94 | 0.050 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2005 | 83 | 0.050 |
Why?
| | Emergency Service, Hospital | 1 | 2016 | 2263 | 0.050 |
Why?
| | Needs Assessment | 1 | 2007 | 389 | 0.050 |
Why?
| | Immunoglobulin G | 1 | 2008 | 892 | 0.050 |
Why?
| | Blood Component Transfusion | 1 | 2005 | 102 | 0.050 |
Why?
| | Aerosols | 1 | 2025 | 183 | 0.050 |
Why?
| | Acute Disease | 2 | 2019 | 994 | 0.050 |
Why?
| | Drug Combinations | 1 | 2005 | 371 | 0.050 |
Why?
| | Alabama | 1 | 2023 | 29 | 0.050 |
Why?
| | Practice Patterns, Physicians' | 2 | 2013 | 1319 | 0.050 |
Why?
| | Follow-Up Studies | 3 | 2021 | 5276 | 0.050 |
Why?
| | Syndrome | 2 | 2014 | 371 | 0.050 |
Why?
| | Simazine | 1 | 2022 | 2 | 0.050 |
Why?
| | ortho-Aminobenzoates | 1 | 2022 | 10 | 0.050 |
Why?
| | Risk Factors | 5 | 2018 | 10569 | 0.050 |
Why?
| | Ventricular Function, Right | 1 | 2025 | 295 | 0.050 |
Why?
| | Glycolysis | 1 | 2025 | 339 | 0.050 |
Why?
| | E-Selectin | 1 | 2023 | 61 | 0.050 |
Why?
| | Antibodies | 1 | 2005 | 399 | 0.050 |
Why?
| | Oxygen | 1 | 2008 | 992 | 0.050 |
Why?
| | Renal Insufficiency | 1 | 2005 | 167 | 0.050 |
Why?
| | Medical Records | 1 | 2023 | 181 | 0.050 |
Why?
| | Glycolipids | 1 | 2023 | 48 | 0.050 |
Why?
| | Healthcare Disparities | 1 | 2009 | 693 | 0.040 |
Why?
| | Data Collection | 1 | 2024 | 632 | 0.040 |
Why?
| | Coronary Artery Disease | 1 | 2008 | 722 | 0.040 |
Why?
| | Agriculture | 1 | 2022 | 102 | 0.040 |
Why?
| | P-Selectin | 1 | 2021 | 28 | 0.040 |
Why?
| | Substance-Related Disorders | 1 | 2011 | 1073 | 0.040 |
Why?
| | Education, Medical, Graduate | 1 | 2007 | 543 | 0.040 |
Why?
| | Models, Theoretical | 1 | 2025 | 584 | 0.040 |
Why?
| | Incidence | 2 | 2021 | 2828 | 0.040 |
Why?
| | Colorado | 3 | 2024 | 4569 | 0.040 |
Why?
| | Blood Pressure | 3 | 2018 | 1747 | 0.040 |
Why?
| | Dietary Exposure | 1 | 2021 | 7 | 0.040 |
Why?
| | Vitrification | 1 | 2021 | 6 | 0.040 |
Why?
| | Oocyte Retrieval | 1 | 2021 | 12 | 0.040 |
Why?
| | Ovarian Hyperstimulation Syndrome | 1 | 2021 | 5 | 0.040 |
Why?
| | Oogenesis | 1 | 2021 | 19 | 0.040 |
Why?
| | Phylogeography | 1 | 2021 | 55 | 0.040 |
Why?
| | Ovulation Induction | 1 | 2021 | 56 | 0.040 |
Why?
| | Anti-Mullerian Hormone | 1 | 2021 | 58 | 0.040 |
Why?
| | Multivariate Analysis | 2 | 2016 | 1493 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 1 | 2023 | 578 | 0.040 |
Why?
| | von Willebrand Factor | 2 | 1998 | 85 | 0.040 |
Why?
| | Monocytes | 1 | 2023 | 542 | 0.040 |
Why?
| | Luteinizing Hormone | 1 | 2021 | 189 | 0.040 |
Why?
| | Cardiac Catheterization | 1 | 2004 | 524 | 0.040 |
Why?
| | Australasia | 1 | 2019 | 2 | 0.040 |
Why?
| | Cryopreservation | 1 | 2021 | 110 | 0.040 |
Why?
| | Metals | 1 | 2021 | 143 | 0.040 |
Why?
| | Follicle Stimulating Hormone | 1 | 2021 | 249 | 0.040 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2021 | 210 | 0.040 |
Why?
| | HIV Infections | 1 | 1994 | 3031 | 0.040 |
Why?
| | Gadolinium | 1 | 2019 | 86 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2018 | 3601 | 0.040 |
Why?
| | Rats | 2 | 2019 | 5570 | 0.040 |
Why?
| | Tissue Distribution | 1 | 2019 | 328 | 0.040 |
Why?
| | Cell Line | 2 | 2015 | 2884 | 0.040 |
Why?
| | Proteinuria | 1 | 2018 | 102 | 0.030 |
Why?
| | Endothelins | 1 | 2018 | 63 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2005 | 1655 | 0.030 |
Why?
| | Guinea Pigs | 1 | 2018 | 163 | 0.030 |
Why?
| | Thrombomodulin | 1 | 1998 | 14 | 0.030 |
Why?
| | Allografts | 1 | 2019 | 149 | 0.030 |
Why?
| | Oxidative Stress | 1 | 2025 | 1371 | 0.030 |
Why?
| | Body Height | 1 | 2018 | 202 | 0.030 |
Why?
| | Victoria | 1 | 2017 | 19 | 0.030 |
Why?
| | Public Health Practice | 1 | 2017 | 64 | 0.030 |
Why?
| | Anemia, Hemolytic | 1 | 2017 | 16 | 0.030 |
Why?
| | Drug Administration Schedule | 2 | 2011 | 766 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2019 | 727 | 0.030 |
Why?
| | Cytochrome P-450 CYP1A1 | 1 | 2016 | 9 | 0.030 |
Why?
| | Fish Proteins | 1 | 2016 | 12 | 0.030 |
Why?
| | Bile | 1 | 2016 | 24 | 0.030 |
Why?
| | Acclimatization | 1 | 2018 | 171 | 0.030 |
Why?
| | Public-Private Sector Partnerships | 1 | 2017 | 45 | 0.030 |
Why?
| | Proteins | 1 | 2023 | 1016 | 0.030 |
Why?
| | Pilot Projects | 2 | 2016 | 1830 | 0.030 |
Why?
| | Intraoperative Complications | 1 | 1998 | 154 | 0.030 |
Why?
| | Polychlorinated Biphenyls | 1 | 2016 | 12 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 1037 | 0.030 |
Why?
| | Blood Coagulation Factors | 1 | 1996 | 54 | 0.030 |
Why?
| | Genetic Markers | 1 | 2017 | 337 | 0.030 |
Why?
| | United States Food and Drug Administration | 1 | 2017 | 198 | 0.030 |
Why?
| | Cross-Sectional Studies | 3 | 2016 | 5726 | 0.030 |
Why?
| | Community Health Services | 1 | 2017 | 232 | 0.030 |
Why?
| | Odorants | 1 | 2016 | 119 | 0.030 |
Why?
| | Mononuclear Phagocyte System | 1 | 1995 | 10 | 0.030 |
Why?
| | Erythrocyte Count | 1 | 1995 | 21 | 0.030 |
Why?
| | Erythrocytes, Abnormal | 1 | 1995 | 14 | 0.030 |
Why?
| | RNA, Messenger | 2 | 2013 | 2831 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 2008 | 3808 | 0.030 |
Why?
| | Arginase | 1 | 2015 | 28 | 0.030 |
Why?
| | Continuity of Patient Care | 1 | 2017 | 284 | 0.030 |
Why?
| | Silicon Dioxide | 1 | 2016 | 120 | 0.030 |
Why?
| | Vitamin B 6 Deficiency | 1 | 1994 | 6 | 0.030 |
Why?
| | Excitatory Amino Acids | 1 | 1994 | 7 | 0.030 |
Why?
| | Amino Acids, Sulfur | 1 | 1994 | 8 | 0.030 |
Why?
| | Siblings | 1 | 2015 | 194 | 0.030 |
Why?
| | Cysteic Acid | 1 | 1994 | 1 | 0.030 |
Why?
| | beta 2-Glycoprotein I | 1 | 1994 | 5 | 0.030 |
Why?
| | Lupus Coagulation Inhibitor | 1 | 1994 | 6 | 0.030 |
Why?
| | Blood Cell Count | 1 | 2014 | 52 | 0.030 |
Why?
| | Antibodies, Anticardiolipin | 1 | 1994 | 7 | 0.030 |
Why?
| | Blood Coagulation | 1 | 1996 | 270 | 0.030 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2015 | 140 | 0.030 |
Why?
| | Hematocrit | 1 | 2014 | 105 | 0.030 |
Why?
| | Interview, Psychological | 1 | 2014 | 93 | 0.030 |
Why?
| | Automation | 1 | 2014 | 102 | 0.030 |
Why?
| | Echocardiography, Doppler | 1 | 2015 | 114 | 0.030 |
Why?
| | Folic Acid Deficiency | 1 | 1994 | 49 | 0.030 |
Why?
| | Penicillins | 1 | 2014 | 59 | 0.030 |
Why?
| | Health Policy | 1 | 2017 | 389 | 0.030 |
Why?
| | Blood Platelets | 1 | 1998 | 392 | 0.030 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2015 | 149 | 0.030 |
Why?
| | Ferritins | 1 | 2014 | 68 | 0.030 |
Why?
| | Vitamin B 12 Deficiency | 1 | 1994 | 78 | 0.030 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2017 | 450 | 0.030 |
Why?
| | Pharmaceutical Services | 1 | 2014 | 77 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 2003 | 0.030 |
Why?
| | Hematologic Tests | 1 | 1994 | 22 | 0.030 |
Why?
| | Homocysteine | 1 | 1994 | 151 | 0.030 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2014 | 107 | 0.030 |
Why?
| | Ownership | 1 | 2014 | 107 | 0.030 |
Why?
| | Smegmamorpha | 1 | 2013 | 6 | 0.030 |
Why?
| | Vascular Resistance | 1 | 2015 | 364 | 0.030 |
Why?
| | DNA Damage | 1 | 2016 | 429 | 0.030 |
Why?
| | Carrier Proteins | 2 | 1995 | 742 | 0.020 |
Why?
| | Catalase | 1 | 2013 | 134 | 0.020 |
Why?
| | Professional Role | 1 | 2014 | 156 | 0.020 |
Why?
| | Cell Membrane Permeability | 1 | 2013 | 85 | 0.020 |
Why?
| | Abdominal Pain | 1 | 2014 | 145 | 0.020 |
Why?
| | Liver Failure, Acute | 1 | 1994 | 53 | 0.020 |
Why?
| | Personnel Selection | 1 | 2014 | 90 | 0.020 |
Why?
| | Mood Disorders | 1 | 2014 | 139 | 0.020 |
Why?
| | Folic Acid | 1 | 1995 | 194 | 0.020 |
Why?
| | Hemoglobin, Sickle | 1 | 2013 | 19 | 0.020 |
Why?
| | Antibiotic Prophylaxis | 1 | 2014 | 127 | 0.020 |
Why?
| | Brain Diseases | 1 | 1994 | 150 | 0.020 |
Why?
| | Permeability | 1 | 2013 | 167 | 0.020 |
Why?
| | Cysteine | 1 | 1994 | 210 | 0.020 |
Why?
| | Methylamines | 1 | 2013 | 40 | 0.020 |
Why?
| | Clinical Protocols | 1 | 2014 | 279 | 0.020 |
Why?
| | Behavior, Animal | 1 | 2016 | 511 | 0.020 |
Why?
| | Equipment Design | 1 | 2014 | 530 | 0.020 |
Why?
| | Erythrocyte Indices | 1 | 2012 | 31 | 0.020 |
Why?
| | Receptors, Cell Surface | 1 | 1995 | 377 | 0.020 |
Why?
| | Minority Groups | 1 | 2014 | 278 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2017 | 784 | 0.020 |
Why?
| | Glycoproteins | 1 | 1994 | 356 | 0.020 |
Why?
| | Vascular Diseases | 1 | 2015 | 248 | 0.020 |
Why?
| | Perioperative Care | 1 | 2014 | 222 | 0.020 |
Why?
| | Social Behavior | 1 | 2014 | 287 | 0.020 |
Why?
| | Choline | 1 | 2013 | 135 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2014 | 917 | 0.020 |
Why?
| | Macrophages, Alveolar | 1 | 2015 | 371 | 0.020 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2013 | 295 | 0.020 |
Why?
| | Cell-Derived Microparticles | 1 | 2012 | 76 | 0.020 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2008 | 3833 | 0.020 |
Why?
| | Physician-Patient Relations | 1 | 2016 | 581 | 0.020 |
Why?
| | Toll-Like Receptor 4 | 1 | 2013 | 276 | 0.020 |
Why?
| | Superoxide Dismutase | 1 | 2013 | 349 | 0.020 |
Why?
| | Inflammation | 1 | 2023 | 2883 | 0.020 |
Why?
| | Sildenafil Citrate | 1 | 2011 | 60 | 0.020 |
Why?
| | Public Health | 1 | 2016 | 560 | 0.020 |
Why?
| | Homozygote | 1 | 2011 | 199 | 0.020 |
Why?
| | Health Status | 1 | 2016 | 819 | 0.020 |
Why?
| | Physical Therapy Modalities | 1 | 2014 | 328 | 0.020 |
Why?
| | Familial Primary Pulmonary Hypertension | 1 | 2011 | 197 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2014 | 1286 | 0.020 |
Why?
| | Up-Regulation | 1 | 2013 | 859 | 0.020 |
Why?
| | Hemodynamics | 2 | 2011 | 1115 | 0.020 |
Why?
| | Wounds and Injuries | 1 | 2018 | 947 | 0.020 |
Why?
| | Respiratory Insufficiency | 1 | 1994 | 331 | 0.020 |
Why?
| | Purines | 1 | 2011 | 186 | 0.020 |
Why?
| | Communication | 1 | 2016 | 953 | 0.020 |
Why?
| | NF-kappa B | 1 | 2013 | 666 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2017 | 3110 | 0.020 |
Why?
| | Pediatrics | 1 | 2017 | 1073 | 0.020 |
Why?
| | Metabolome | 1 | 2013 | 380 | 0.020 |
Why?
| | Walking | 1 | 2014 | 558 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2015 | 2509 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2017 | 2516 | 0.020 |
Why?
| | Gastrointestinal Diseases | 1 | 2011 | 209 | 0.020 |
Why?
| | Pneumonia | 1 | 2015 | 640 | 0.020 |
Why?
| | Sepsis | 1 | 1995 | 634 | 0.020 |
Why?
| | Databases, Factual | 1 | 2014 | 1452 | 0.020 |
Why?
| | Exercise Test | 1 | 2011 | 618 | 0.020 |
Why?
| | Gene Expression | 1 | 2013 | 1502 | 0.020 |
Why?
| | Genotype | 1 | 2013 | 1828 | 0.020 |
Why?
| | Comorbidity | 1 | 2012 | 1632 | 0.020 |
Why?
| | Chelation Therapy | 1 | 2007 | 10 | 0.020 |
Why?
| | Infant | 3 | 2014 | 9849 | 0.020 |
Why?
| | Diabetic Angiopathies | 1 | 2008 | 251 | 0.020 |
Why?
| | Cardiovascular Diseases | 1 | 2018 | 2095 | 0.020 |
Why?
| | Calcinosis | 1 | 2008 | 235 | 0.020 |
Why?
| | Alanine Transaminase | 1 | 2007 | 147 | 0.020 |
Why?
| | Health Personnel | 1 | 2013 | 732 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2018 | 2869 | 0.010 |
Why?
| | Health Services | 1 | 2007 | 113 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2011 | 2083 | 0.010 |
Why?
| | Muscle, Skeletal | 1 | 2016 | 1799 | 0.010 |
Why?
| | Mental Disorders | 1 | 1994 | 1123 | 0.010 |
Why?
| | Models, Biological | 1 | 2013 | 1826 | 0.010 |
Why?
| | Program Development | 1 | 2007 | 364 | 0.010 |
Why?
| | Gas Chromatography-Mass Spectrometry | 2 | 1995 | 131 | 0.010 |
Why?
| | Administration, Oral | 1 | 2007 | 834 | 0.010 |
Why?
| | Isotope Labeling | 2 | 1995 | 81 | 0.010 |
Why?
| | Critical Illness | 1 | 2010 | 872 | 0.010 |
Why?
| | Academic Medical Centers | 1 | 2007 | 534 | 0.010 |
Why?
| | Logistic Models | 1 | 2008 | 2088 | 0.010 |
Why?
| | Respiratory Tract Infections | 1 | 2007 | 393 | 0.010 |
Why?
| | Referral and Consultation | 1 | 2007 | 823 | 0.010 |
Why?
| | Attitude of Health Personnel | 1 | 2008 | 1168 | 0.010 |
Why?
| | Insulin Resistance | 1 | 2008 | 1253 | 0.010 |
Why?
| | Delivery of Health Care | 1 | 2007 | 936 | 0.010 |
Why?
| | Physicians | 1 | 2008 | 925 | 0.010 |
Why?
| | Liver Function Tests | 1 | 1996 | 98 | 0.010 |
Why?
| | Respiration | 1 | 1996 | 209 | 0.010 |
Why?
| | Folate Receptors, GPI-Anchored | 1 | 1995 | 5 | 0.010 |
Why?
| | 4-Aminobenzoic Acid | 1 | 1995 | 8 | 0.010 |
Why?
| | Vacuoles | 1 | 1995 | 38 | 0.010 |
Why?
| | Lactobacillus | 1 | 1995 | 27 | 0.010 |
Why?
| | Radionuclide Imaging | 1 | 1995 | 113 | 0.010 |
Why?
| | Reference Standards | 1 | 1995 | 181 | 0.010 |
Why?
| | Carbon Isotopes | 1 | 1995 | 142 | 0.010 |
Why?
| | Aspartic Acid | 1 | 1994 | 86 | 0.010 |
Why?
| | Neurotransmitter Agents | 1 | 1994 | 80 | 0.010 |
Why?
| | Deuterium | 1 | 1994 | 97 | 0.010 |
Why?
| | Disease Susceptibility | 1 | 1995 | 348 | 0.010 |
Why?
| | Reference Values | 1 | 1994 | 805 | 0.010 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 1 | 1994 | 223 | 0.010 |
Why?
| | Cattle | 1 | 1995 | 1004 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 1995 | 1976 | 0.000 |
Why?
| | Brain | 1 | 1994 | 2886 | 0.000 |
Why?
|
|
Hassell's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|